skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon


HBW Insightでは一般用医薬品(OTC)、ビタミンなどのサプリメント(栄養補助食品)、化粧品の3分野を主にカバーして、世界のコンシューマーヘルスケア産業のニュースをお伝えします。







  • 企業の合併&買収
  • 新製品発表&上市
  • 広告戦略
  • レギュレーションの変更&施行
  • スイッチOTC医薬品
  • 小売業の発展



  • 規制およびコンプライアンス
  • 法規制の動向
  • 安全性の課題



  • 増加傾向にある栄養補助食品
  • 規制上および法律上の落とし穴
  • 競合製品の開発状況
  • マーケティング戦略
  • 広告の取り扱いに関する課題
  • 新成分に関する表示



  • HBW Insight : コンシューマーヘルスケア産業のニュース

    US Senate Passes First Monograph Reform Bill After House Passed Three

    11 Dec 2019

    Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Fragrance Creators Association Readies New Consumer Website To Cap 'Year For The Public'

    11 Dec 2019

    Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Future of CBD In Supplements: NDI Notification Looms As Regulatory Path

    06 Dec 2019


    Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    GSK Launches OTC Fluticasone In Japan Following Switch

    By Tom Gallen 06 Dec 2019


    GSK has launched Flunase in Japan following the switch of fluticasone propionate. JSMI’s Toshi Tominaga gives his assessment of the product’s prospects as an OTC drug.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Sunscreen Industry Faces Major Challenge In GRASE Push That OTC Monograph Reform Would Solve

    28 Nov 2019

    Industry advocates working to support GRASE determinations for eight UV filters are faced with a dilemma. They would like to share nonpublic studies with the FDA on a confidential basis – at least to get initial temperature readings from the agency as to the studies’ usefulness in addressing data gaps – but under the current OTC monograph framework, no such pathway exists.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Complicated Regulatory Odyssey Steers FDA Toward Rule On CBD In Supplements

    27 Nov 2019

    Before Congress de-scheduled hemp at end of 2018 and forced agency's hand on considering lawful use of ingredients derived from the plant in supplements and food, the floodgate for sales of the products was opened in 2013 by a DoJ policy change to de-emphasize enforcement of most federal marijuana laws.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Aspirational Products Driving Growth In Developed OTC Markets

    22 Nov 2019

    Aspirational OTC products such as probiotics are outstripping demand for traditional symptom relievers, IQVIA's Andy Tisman told the recent Ceuta International Conference. Consumer health players must adapt their portfolios to cater for the more health conscious, informed, and digitally-connected consumer, Tisman advises

    Topic business-strategies

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Vitamin D, Omega-3 No Help For Diabetics Against CKD, VITAL Data Show

    13 Nov 2019

    In latest study casting doubt on the nutrients' effect on chronic illness, researchers find vitamin D and fish oil ineffective in staving off type 2 diabetics' kidney failure. Editorial also published in JAMA says further research is needed to analyze the nutrients’ possible benefits to diabetics with chronic kidney disease.

    Topic clinical-trials

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Novartis Wins Second Landmark German Case, This Time For Probiotics

    13 Nov 2019

    Following a landmark win against the German government for the Rx-to-OTC switch of desloratadine last month, Novartis has again secured a victory in the German Higher Court system, this time to continue marketing its Biosan probiotics range in the country.

    Topic company-analysis policy-and-regulation

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Homeopathic Market Doesn't 'Disappear' - FDA Forced To Act

    08 Nov 2019

    "This was an area that the agency thought was just going to disappear on its own," says Freddie Ann Hoffman, who chaired FDA homeopathic working group that helped develop CPG adopted in 1988 to allow sales of homeopathics to continue without pre-market approval.

    Topic fda policy-and-regulation

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Zantac Recall And EU Regulatory Issues Hurt Sanofi In Q3

    By Tom Gallen 08 Nov 2019

    Recalling Zantac in North America over contamination concerns and tightening regulatory requirements in Europe combined to impede growth at Sanofi Consumer Healthcare in Q3. New CEO Paul Hudson says he is still taking time to get to know the business before making any strategic moves.

    Topic policy-and-regulation

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    FDA Adds Homeopathic Enforcement Details, Subtracts Compliance Policy Guide

    01 Nov 2019

    Revised draft guidance identifies types of homeopathics posing "higher risks to public health." FDA withdraws 1988 compliance policy guide that allows homeopathic to be available even though they are not subject to pre-market approval or other review process agency imposes on all other drugs.  

    Topic fda policy-and-regulation

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Japan's New Rx-To-OTC Procedure Exacerbating Switch Blockage Says JSMI

    07 Aug 2019

    Japan's New Rx-To-OTC Procedure Exacerbating Switch Blockage Says JSMI

    Japan's new Rx-to-OTC switch procedure has exacerbated a "switch lag" compared with developed countries, says Japan Self-Medication Industry senior adviser Toshi Tominaga in an exclusive interview with HBW Insight. Tominaga proposes improvements such as self-care education for consumers and drug usage advice included by firms in switch applications to help balance the risk-benefit decisions of expert judges.

    Topic Policy and regulation

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Long-term E-cigarette Use Could Spark More Smoking, French Study Suggests

    29 Jul 2019

    Long-term E-cigarette Use Could Spark More Smoking, French Study Suggests

    Research in JAMA Internal Medicine studied "longitudinal associations between [e-cigarette] use and tobacco smoking patterns in a large population-based cohort study" and found use was associated with reduction in smoking and an increased probability of smoking cessation. But the researchers saw that e-cigarette users who quit tobacco "tended to relapse to smoking more frequently than" former smokers who didn't use e-cigarettes.

    Topic medtech

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Cannabidiol - HBW Insight coverage

    10 Jul 2019

    Cannabidiol - HBW Insight coverage

    Cannabidiol (CBD) is being looked at more and more by health beauty and wellness companies for new OTC drugs, cosmetics and supplements. It is highly controversial because while CBD has many natural benefits for treating a variety of symptoms and conditions, it is the active ingredient in cannabis which comes from the hemp plant.

    Topic Drug review Drug approval



Richard Faint

Management, Head of Medtech
Richard Faint

Eileen Francis

Reporter-Journalist, Reporter

Washington DC

Eileen Francis

Eileen specializes in

  • Policy and Regulation
  • Commercial Strategy
  • Dietary Supplements
  • OTC

+19 year(s) experience


Ryan Nelson

Editor, Executive Editor - Health, Beauty and Wellness Insight
Ryan Nelson

Ryan specializes in

  • Policy and Regulation
  • Commercial Strategy
  • Cosmetics
  • Dietary Supplements
  • Market Access

+15 year(s) experience




電話:+81 (0)3 6273 4260